BUZZ-Generation Bio jumps on strategic review, deep job cuts

Reuters

2025/08/13

BUZZ-<a href="https://laohu8.com/S/GBIO">Generation Bio</a> jumps on strategic review, deep job cuts

** Shares of drug developer Generation Bio GBIO.O rise 30% to $5.28 premarket

** Late on Tuesday co said it is exploring strategic alternatives, including a sale, merger, or asset deal, with TD Cowen advising

** Co also restructuring with about a 90% workforce reduction by end of October

** Co posted Q2 sales of $765,000, well below analysts' est of $3.1 mln - LSEG

** Co reported Q2 loss per share of $3.12, compared to estimate loss of 2.85/share - LSEG

** Co also said its experimental drug delivery system successfully targeted immune cells in monkey studies for the first time and showed promise for treating autoimmune diseases by blocking key immune cell proteins

** As of last close, stock down 61% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2559601747"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559601747\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559601747?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559601747","market":"us","top_or_hot":-1,"title":"BUZZ-Generation Bio jumps on strategic review, deep job cuts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/GBIO\">Generation Bio</a> jumps on strategic review, deep job cuts</title></head><body><p>** Shares of drug developer Generation Bio <span>GBIO.O</span> rise 30% to $5.28 premarket</p><p>** Late on Tuesday co said it is exploring strategic alternatives, including a sale, merger, or asset deal, with TD Cowen advising</p><p>** Co also restructuring with about a 90% workforce reduction by end of October</p><p>** Co posted <a href=\"https://laohu8.com/S/QTWO\">Q2</a> sales of $765,000, well below analysts' est of $3.1 mln - LSEG</p><p>** Co reported Q2 loss per share of $3.12, compared to estimate loss of 2.85/share - LSEG</p><p>** Co also said its experimental drug delivery system successfully targeted immune cells in monkey studies for the first time and showed promise for treating autoimmune diseases by blocking key immune cell proteins</p><p>** As of last close, stock down 61% YTD</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Generation Bio jumps on strategic review, deep job cuts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Generation Bio jumps on strategic review, deep job cuts\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-13 19:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/GBIO\">Generation Bio</a> jumps on strategic review, deep job cuts</title></head><body><p>** Shares of drug developer Generation Bio <span>GBIO.O</span> rise 30% to $5.28 premarket</p><p>** Late on Tuesday co said it is exploring strategic alternatives, including a sale, merger, or asset deal, with TD Cowen advising</p><p>** Co also restructuring with about a 90% workforce reduction by end of October</p><p>** Co posted <a href=\"https://laohu8.com/S/QTWO\">Q2</a> sales of $765,000, well below analysts' est of $3.1 mln - LSEG</p><p>** Co reported Q2 loss per share of $3.12, compared to estimate loss of 2.85/share - LSEG</p><p>** Co also said its experimental drug delivery system successfully targeted immune cells in monkey studies for the first time and showed promise for treating autoimmune diseases by blocking key immune cell proteins</p><p>** As of last close, stock down 61% YTD</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nL4N3U50RL:1","article_id":"2559601747","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559601747","pubTimestamp":1755085930,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Generation Bio jumps on strategic review, deep job cuts** Shares of drug developer Generation Bio GBIO.O rise 30% to $5.28 premarket** Late on Tuesday co said it is exploring strategic alternatives, including a sale, merger, or asset deal, with TD Cowen advising** Co also restructuring with about a 90% workforce reduction by end of October** Co posted Q2 sales of $765,000, well below analysts' est of $3.1 mln - LSEG** Co reported Q2 loss per share of $3.12, compared to estimate loss of 2.85/share - LSEG** Co also said its experimental drug delivery system successfully targeted immune cells in monkey studies for the first time and showed promise for treating autoimmune diseases by blocking key immune cell proteins** As of last close, stock down 61% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GBIO":"Generation Bio Co.","BK4584":"避孕概念"},"translate_title":"BUZZ-Generation Bio因战略审查和大幅裁员而大幅上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GBIO":0.9},"content_text":"BUZZ-Generation Bio jumps on strategic review, deep job cuts** Shares of drug developer Generation Bio GBIO.O rise 30% to $5.28 premarket** Late on Tuesday co said it is exploring strategic alternatives, including a sale, merger, or asset deal, with TD Cowen advising** Co also restructuring with about a 90% workforce reduction by end of October** Co posted Q2 sales of $765,000, well below analysts' est of $3.1 mln - LSEG** Co reported Q2 loss per share of $3.12, compared to estimate loss of 2.85/share - LSEG** Co also said its experimental drug delivery system successfully targeted immune cells in monkey studies for the first time and showed promise for treating autoimmune diseases by blocking key immune cell proteins** As of last close, stock down 61% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}